Disc Medicine (IRON) Price & Analysis

Compare

467 Followers

IRON Stock Chart & Stats

Day’s Range― - ―

52-Week Range$30.82 - $68.73

Previous CloseN/A

Volume41.94K

Average Volume (3M)349.68K

Market Cap

$2.11B

Enterprise Value$1.24B

Total Cash (Recent Filing)$649.97M

Total Debt (Recent Filing)$30.92M

Price to Earnings (P/E)―

Beta1.80

Next Earnings

Nov 06, 2025

EPS Estimate

-1.46

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.58

Shares Outstanding34,765,580

10 Day Avg. Volume386,760

30 Day Avg. Volume349,676

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.59

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-30.90K

Enterprise Value/Ebitda-9.27

Forecast

1Y Price Target

$93.86

Price Target Upside56.80% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessCompelling efficacy in the BEACON and AURORA studies with significant protoporphyrin IX reduction and sunlight tolerance improvements indicates strong potential for bitopertin's market success.

Financial PositionThe company's robust financial position, with $650M in cash, is expected to fund operations into 2028, supporting ongoing and future developmental activities.

Regulatory ApprovalIRON announced positive FDA feedback from a pre-NDA meeting for bitopertin in erythropoietic protoporphyria, supporting an accelerated approval pathway.

Bears Say

Market CompetitionThe development continues to reinforce the accelerated approval pathway in EPP, where bitopertin will be the first drug to pursue this regulatory path.

Regulatory ChallengesThe company narrowed timing guidance for NDA submission to October 2025 and reiterated plans to leverage an accelerated approval pathway.

Disc Medicine News

Disc Medicine reports Q2 EPS ($1.58), consensus ($1.14)

“We are pleased with the continued momentum this past quarter, highlighted by clinical data presentations that support further...

10d ago

IRON

Disc Medicine announces feedback from pre-NDA meeting with FDA for bitopertin

Disc Medicine (IRON) announced positive feedback from its pre-New Drug Application, NDA, meeting with the U.S. Food and...

27d ago

IRON

Disc Medicine initiated with a Buy at Truist

Truist initiated coverage of Disc Medicine (IRON) with a Buy rating and $86 price target Disc Medicine is...

27d ago

IRON

Disc Medicine Reports Q2 2025 Financial Results and Clinical Progress

Disc Medicine, Inc. ( ($IRON) ) has released its Q2 earnings. Here is a breakdown of the information...

9d ago

IRON

Disc Medicine: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Disc Medicine today and set a price target...

9d ago

IRON

Disc Medicine’s Strategic Advancements and Regulatory Progress Drive Buy Rating

Leerink Partners analyst Thomas Smith has maintained their bullish stance on IRON stock, giving a Buy rating on...

25d ago

IRON

Buy Rating for Disc Medicine: DISC-0974’s Potential in Myelofibrosis-Related Anemia

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Disc Medicine. The associated price target...

29d ago

IRON

Disc Medicine Elects Nadim Ahmed as Director

Disc Medicine ( ($IRON) ) has provided an announcement. On July 9, 2025, Disc Medicine‘s Board of Directors...

1M ago

IRON

Disc Medicine appoints Ahmed to its Board of Directors

Disc Medicine (IRON) announced the appointment of Nadim Ahmed to its Board of Directors. Ahmed is currently the...

1M ago

CGEM

IRON

3 Best Stocks to Buy Now, 7/4/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1M ago

IRON

Disc Medicine assumed with an Overweight at Morgan Stanley

Morgan Stanley assumed coverage of Disc Medicine (IRON) with an Overweight rating and $85 price target The near-term...

1M ago

IRON

Disc Medicine’s Promising Future: Buy Rating Backed by Strong Pipeline and Growth Potential

In a report released yesterday, Sean Laaman from Morgan Stanley maintained a Buy rating on Disc Medicine, with...

1M ago

IRON

Promising Potential of Bitopertin in Treating Erythropoietic Protoporphyria Drives Buy Rating for Disc Medicine

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Disc Medicine today and set a price target...

1M ago

IRON

Disc Medicine’s Promising Hematology Pipeline and Positive Trial Results Earn Buy Rating

In a report released on June 16, Thomas Smith from Leerink Partners maintained a Buy rating on Disc...

2M ago

IRON

IRON FAQ

What was Disc Medicine’s price range in the past 12 months?

Disc Medicine lowest stock price was $30.82 and its highest was $68.73 in the past 12 months.

What is Disc Medicine’s market cap?

Disc Medicine’s market cap is $2.11B.

When is Disc Medicine’s upcoming earnings report date?

Disc Medicine’s upcoming earnings report date is Nov 06, 2025 which is in 81 days.

How were Disc Medicine’s earnings last quarter?

Disc Medicine released its earnings results on Aug 07, 2025. The company reported -$1.58 earnings per share for the quarter, missing the consensus estimate of -$1.128 by -$0.452.

Is Disc Medicine overvalued?

According to Wall Street analysts Disc Medicine’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Disc Medicine pay dividends?

Disc Medicine does not currently pay dividends.

What is Disc Medicine’s EPS estimate?

Disc Medicine’s EPS estimate is -1.46.

How many shares outstanding does Disc Medicine have?

Disc Medicine has 34,765,580 shares outstanding.

What happened to Disc Medicine’s price movement after its last earnings report?

Disc Medicine reported an EPS of -$1.58 in its last earnings report, missing expectations of -$1.128. Following the earnings report the stock price went down -3.271%.

Which hedge fund is a major shareholder of Disc Medicine?

Currently, no hedge funds are holding shares in IRON

Disc Medicine Stock Smart Score

Neutral

Fundamentals

Return on Equity

-26.36%

Trailing 12-Months

Asset Growth

30.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Disc Medicine

Disc Medicine (IRON) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for the treatment of hematologic diseases. The company's core products are designed to address conditions related to iron homeostasis, such as anemia and iron overload disorders. Disc Medicine aims to innovate within the hematology sector by developing drugs that can provide effective solutions for patients with unmet medical needs.

Disc Medicine (IRON) Earnings & Revenues

Historic Earnings Reports

IRON Stock 12 Month Forecast

Average Price Target

$93.86

▲(56.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"42":"$42","121":"$121","61.75":"$61.8","81.5":"$81.5","101.25":"$101.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[42,61.75,81.5,101.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.97,63.66461538461538,68.35923076923076,73.05384615384615,77.74846153846154,82.44307692307692,87.1376923076923,91.8323076923077,96.52692307692308,101.22153846153846,105.91615384615385,110.61076923076922,115.30538461538461,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.97,61.65384615384615,64.33769230769231,67.02153846153846,69.70538461538462,72.38923076923076,75.07307692307693,77.75692307692307,80.44076923076923,83.12461538461538,85.80846153846154,88.49230769230769,91.17615384615385,{"y":93.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.97,60.20307692307692,61.43615384615384,62.669230769230765,63.902307692307694,65.13538461538461,66.36846153846153,67.60153846153847,68.83461538461539,70.06769230769231,71.30076923076923,72.53384615384616,73.76692307692308,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":43.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.82,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.73,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.13,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.97,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >